Cyclo Therapeutics Valuation
Is CYTH undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CYTH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate CYTH's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate CYTH's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CYTH?
Other financial metrics that can be useful for relative valuation.
| What is CYTH's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | US$34.75m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 24.6x |
| Enterprise Value/EBITDA | -1.3x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does CYTH's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 27.9x | ||
ICCC ImmuCell | 2.2x | n/a | US$39.0m |
FBIO Fortress Biotech | 0.4x | 14.1% | US$34.8m |
XGN Exagen | 0.5x | 13.0% | US$24.1m |
GDTC CytoMed Therapeutics | 108.5x | 33.9% | US$24.8m |
CYTH Cyclo Therapeutics | 32.3x | 57.9% | US$34.7m |
Price-To-Sales vs Peers: CYTH is expensive based on its Price-To-Sales Ratio (32.3x) compared to the peer average (27.9x).
Price to Earnings Ratio vs Industry
How does CYTH's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: CYTH is expensive based on its Price-To-Sales Ratio (32.3x) compared to the US Biotechs industry average (13.4x).
Price to Sales Ratio vs Fair Ratio
What is CYTH's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 32.3x |
| Fair PS Ratio | 15.3x |
Price-To-Sales vs Fair Ratio: CYTH is expensive based on its Price-To-Sales Ratio (32.3x) compared to the estimated Fair Price-To-Sales Ratio (15.3x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.